NCT03301896View on ClinicalTrials.gov

Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Solid Tumors
Interventions
DRUG

LHC165

LHC165 intratumoral injection

BIOLOGICAL

PDR001

PDR001 infusion

Trial Locations (9)

2610

Novartis Investigative Site, Wilrijk

20141

Novartis Investigative Site, Milan

28009

Novartis Investigative Site, Madrid

77030

MD Anderson Cancer Center, Houston

89081

Novartis Investigative Site, Ulm

90095

UCLA, Los Angeles

104 0045

Novartis Investigative Site, Chuo Ku

03080

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY